Androgen receptor promotes arachidonic acid metabolism and angiogenic microenvironment in AFP-negative hepatocellular carcinoma
Zhilong Lin, Xiaofei Liu, Houwei Wang, Shumin Li, Ziqiang Miao, Jing Yang, Yuting Zhang, Kai Lei, Yifan Wu, Youmei Kang, Ruoyin Zheng, Zonglin Xie, Yixi Wen, Xiaoxue Ren, Chunxiao Liu, Alfred Sze‐Lok Cheng, Yubin Xie, Shuling Chen, Ming Kuang, Sui Peng, Zhenwei Peng, Zihao Dai
Abstract
Alpha-fetoprotein (AFP) is a classic biomarker for hepatocellular carcinoma (HCC). AFP-positive HCC (AFP+ HCC) has been intensively investigated; however, the genomic, transcriptomic and microenvironmental characteristics of AFP-negative HCC (AFP− HCC) remain to be deciphered. Here we show that tumors display mild differences in genetic alterations between AFP− HCC and AFP+ HCC patients, while AFP− HCC exhibits hyperactive arachidonic acid metabolism. Furthermore, the transcription activity of androgen receptor (AR) is significantly increased in AFP− HCC and plays a positive regulatory role in arachidonic acid metabolism and its metabolite 11,12-epoxyeicosatrienoic acid (11,12-EET). The tumor-derived 11,12-EET exhibits high affinity for EGFR that promotes the migration and tube formation of endothelial cells in vitro. Combination of lenvatinib and bicalutamide (an AR antagonist) enhances the therapeutic efficacy for AFP− HCC. Overall, we uncover the AR-mediated hyperactive arachidonic acid metabolism in AFP− HCC, and reveal AR-11,12-EET-EGFR axis-induced angiogenesis, providing a promising strategy of combined AR antagonist with lenvatinib for AFP− HCC treatment. Alpha-fetoprotein is a known biomarker for hepatocellular carcinoma. Here, the authors analyse differences between AFP positive and negative patients to identify alterations in androgen receptor signalling.